Septic shock: Difference between revisions

Jump to navigation Jump to search
No edit summary
Line 60: Line 60:
[[Category:Infectious disease]]
[[Category:Infectious disease]]
[[Category:Emergency medicine]]
[[Category:Emergency medicine]]
 
{{Intensive care medicine}}
{{SIB}}
{{SIB}}



Revision as of 18:11, 25 January 2009

Template:DiseaseDisorder infobox

WikiDoc Resources for Septic shock

Articles

Most recent articles on Septic shock

Most cited articles on Septic shock

Review articles on Septic shock

Articles on Septic shock in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Septic shock

Images of Septic shock

Photos of Septic shock

Podcasts & MP3s on Septic shock

Videos on Septic shock

Evidence Based Medicine

Cochrane Collaboration on Septic shock

Bandolier on Septic shock

TRIP on Septic shock

Clinical Trials

Ongoing Trials on Septic shock at Clinical Trials.gov

Trial results on Septic shock

Clinical Trials on Septic shock at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Septic shock

NICE Guidance on Septic shock

NHS PRODIGY Guidance

FDA on Septic shock

CDC on Septic shock

Books

Books on Septic shock

News

Septic shock in the news

Be alerted to news on Septic shock

News trends on Septic shock

Commentary

Blogs on Septic shock

Definitions

Definitions of Septic shock

Patient Resources / Community

Patient resources on Septic shock

Discussion groups on Septic shock

Patient Handouts on Septic shock

Directions to Hospitals Treating Septic shock

Risk calculators and risk factors for Septic shock

Healthcare Provider Resources

Symptoms of Septic shock

Causes & Risk Factors for Septic shock

Diagnostic studies for Septic shock

Treatment of Septic shock

Continuing Medical Education (CME)

CME Programs on Septic shock

International

Septic shock en Espanol

Septic shock en Francais

Business

Septic shock in the Marketplace

Patents on Septic shock

Experimental / Informatics

List of terms related to Septic shock

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [2] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.

Overview

Septic shock is a serious medical condition caused by decreased tissue perfusion and oxygen delivery as a result of infection and sepsis. It can cause multiple organ failure and death. Its most common victims are children, immunocompromised individuals, and the elderly, as their immune systems cannot cope with the infection as well as those of full-grown adults. The mortality rate from septic shock is approximately 50%.

Definition of septic shock

To diagnose septic shock[1] the following two criteria must be met:

  1. Evidence of infection, through a positive blood culture.
  2. Refractory hypotension - hypotension despite adequate fluid resuscitation.
    • In adults it is defined as a systolic blood pressure < 90 mmHg, or a MAP < 60 mmHg, without the requirement for inotropic support, or a reduction of 40 mmHg in the systolic blood pressure from baseline.
    • In children it is BP < 2 SD of the normal blood pressure.

In addition to the two criteria above, two or more of the following must be present:

  • Heart rate > 90 beats per minute.
  • Body temperature < 36 or > 38°C.
  • Hyperventilation (high respiratory rate) > 20 breaths per minute or, on blood gas, a PaCO2 less than 32 mmHg.
  • White blood cell count < 4000 cells/mm³ or > 12000 cells/mm³ (< 4 x 109 or > 12 x 109 cells/L).

Types

A subclass of distributive shock, shock refers specifically to decreased tissue perfusion resulting in end-organ dysfunction. Cytokines TNFα, IL-1β, IL-6 released in a large scale inflammatory response results in massive vasodilation, increased capillary permeability, decreased systemic vascular resistance, and hypotension. Hypotension reduces tissue perfusion pressure and thus tissue hypoxia ensues. Finally, in an attempt to offset decreased blood pressure, ventricular dilatation and myocardial dysfunction will occur.

Causes

The process of infection by bacteria or fungi can result in systemic signs and symptoms that are variously described. In rough order of severity, these are bacteremia or fungemia; septicemia; sepsis, severe sepsis or sepsis syndrome; septic shock; refractory septic shock; multiple organ dysfunction syndrome, and death.

The condition develops as a response to certain microbial molecules which trigger the production and release of cellular mediators, such as tumor necrosis factors (TNF); these act to stimulate immune response. Besides TNFα, other cytokines involved in the development of septic shock include interleukin-1β, and interferon γ.

Treatment

Treatment primarily consists of 1) Volume resuscitation 2) Early antibiotic administration 3) Rapid source identification and control and 4) Support of major organ dysfunction.

Among the choices for pressors, a randomized controlled trial concluded that there was no difference between norepinephrine (plus dobutamine as needed for cardiac output) versus epinephrine.[2]

Antimediator agents may be of some limited use in severe clinical situations:

References

  1. Tslotou AG, Sakorafas GH, Anagnostopoulos G, Bramis J. Septic shock; current pathogenetic concepts from a clinical perspective. Med Sci Monit. 2005 Mar;11(3):RA76-85. PMID 15735579 Full Text.
  2. Annane D, Vignon P, Renault A; et al. (2007). "Norepinephrine plus dobutamine versus epinephrine alone for management of septic shock: a randomised trial". Lancet. 370 (9588): 676–84. doi:10.1016/S0140-6736(07)61344-0. PMID 17720019.
  3. Annane D, Sebille V, Charpentier C, Bollaert PE, Francois B, Korach JM, Capellier G, Cohen Y, Azoulay E, Troche G, Chaumet-Riffaut P, Bellissant E. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA. 2002 Aug 21;288(7):862-71. PMID 12186604
  4. Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, Steingrub JS, Garber GE, Helterbrand JD, Ely EW, Fisher CJ Jr; Recombinant human protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study group. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med. 2001 Mar 8;344(10):699-709. PMID 11236773
  5. Levi M, Levy M, Williams MD; et al. (2007). "Prophylactic heparin in patients with severe sepsis treated with drotrecogin alfa (activated)". Am. J. Respir. Crit. Care Med. 176 (5): 483–90. doi:10.1164/rccm.200612-1803OC. PMID 17556722.

See also

Template:SIB sk:Septický šok sv:Septisk chock


Template:WikiDoc Sources